What Intuitive Fosun Hong Kong does

Intuitive Fosun Hong Kong is the commercial entity for a joint venture between Intuitive Surgical (NASDAQ: ISRG) and Fosun, established in May 2017 under the mandate of "China manufacturing, co-development, global sales" to localize and distribute Intuitive's surgical robotics portfolio in the China market. The company sells the domestically manufactured Da Vinci Xi surgical system — a robotic-assisted minimally invasive surgery platform used across general surgery, urology, gynecology, and thoracic specialties — together with the Ion bronchial navigation control system for peripheral lung nodule diagnosis and lung cancer intervention. As of December 2025, more than 500 Da Vinci systems have been deployed in mainland China, Hong Kong, and Macau, the installed base has served over 860,000 patients, and more than 20,000 medical professionals have completed Da Vinci training programs.

The business is an enterprise field-sales model selling directly to hospitals and healthcare institutions, with revenue generated from three streams: capital hardware sales of Da Vinci Xi and Ion systems, professional services covering surgeon and OR-staff training delivered through the Intuitive Fosun Innovation Centers, and recurring service and support contracts on the installed base. Pricing is not publicly disclosed and is handled through enterprise quotations and multi-year contracts. Go-to-market is supplemented by medical-industry conferences, university partnerships (including a Jiaotong Medical School industry-academia program), and a WeChat-led PR function. The company is not publicly traded; it operates under a joint-venture ownership structure with Intuitive Surgical providing core technology and Fosun providing local market access, regulatory navigation, and manufacturing.

In June 2024, Intuitive Fosun opened its Shanghai headquarters and industrialization base — a roughly 700 million RMB investment representing Intuitive's largest integrated R&D, production, and training facility in the Asia-Pacific region. This facility underpins the localization of Da Vinci manufacturing and the introduction of extended-life surgical instruments designed to lower hospital operating costs. In May 2024, the company announced a partnership with 与睿创新 (YuRuiChuangXin) to explore AI-enabled robotic-assisted surgery, signaling an intent to move up the software stack from pure hardware systems toward intelligence-augmented surgical capability. The company holds an Internet Drug Information Service Qualification Certificate for the Shanghai region and operates its digital properties under a Chinese ICP filing.

Name

Intuitive Fosun Hong Kong

Legal name

直观复星医疗器械技术（上海）有限公司

Website

https://intufosun.hk

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Intuitive Fosun Hong Kong is a joint venture between Intuitive Surgical and Fosun that localizes, manufactures, and sells the Da Vinci Xi robotic surgical system and Ion bronchoscopy navigation system to hospitals across mainland China, Hong Kong, and Macau.

Ownership category

akta.pro rank

Product category

Surgical Robotics Systems

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)

akta.pro secondary industries

Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine) (HLAHAEAL), Healthcare & Assistive Robotics (HDAAAIAC), Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity) (HLAHADAE)

Keywords

• Surgical robotics systems
• Robotic-assisted surgery
• Minimally invasive surgery
• Bronchoscopy navigation systems
• Medical device manufacturing

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales and Service: Direct sales and service of surgical robotics systems including the Da Vinci Xi platform and Ion navigation system to hospitals and healthcare institutions, with ongoing service and support contracts.
2. Surgical System Training Services: Training services for medical professionals on Da Vinci surgical robot operation, contributing to healthcare worker education ecosystem.
3. Service and Support Contracts: Ongoing maintenance, support, and service agreements for installed surgical systems.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Intuitive Fosun Hong Kong develops, manufactures, sells, and services robotic-assisted surgical systems (domestically manufactured Da Vinci Xi platform and Ion bronchoscopy navigation control system) for hospitals and healthcare institutions in China, Hong Kong, and Macau. The company also provides training programs for surgeons and medical professionals, along with ongoing maintenance and service contracts for installed systems.

Product overview

Intuitive Fosun (直观复星) offers a portfolio of robotic-assisted surgical and diagnostic systems, comprising the domestically manufactured Da Vinci Xi surgical system and the Ion bronchoscopy navigation control system, along with associated service offerings. The company is a joint venture between Intuitive Surgical and Fosun, established in May 2017, focused on precision medicine with 'China manufacturing, co-development, global sales' as its guiding principle. As of December 2025, the company's systems have benefited over 860,000 patients, with over 500 Da Vinci surgical robots deployed and more than 20,000 medical professionals trained across mainland China and Hong Kong/Macau regions.

Differentiator

Problem solved

Functional benefit

Brands

• Da Vinci Surgical System (达芬奇手术系统): Robotic-assisted minimally invasive surgery system including domestically manufactured Da Vinci Xi system.
• Ion Endoscopic System (Ion支气管导航操作控制系统)

Products and services

• Domestic Da Vinci Xi Surgical System (国产达芬奇Xi手术系统) Robotic-assisted minimally invasive surgical system manufactured locally in China for hospitals and healthcare institutions. The system helps medical staff improve surgical efficiency, reduces costs for healthcare institutions, and provides high-quality minimally invasive treatment for patients across general surgery, urology, gynecology, and thoracic procedures.
• Ion Bronchoscopy Navigation and Operation Control System (Ion支气管导航操作控制系统) Bronchoscopy navigation control system designed to help clinicians improve diagnostic rates for peripheral lung nodules, provide minimally invasive treatment, and improve survival rates for lung cancer patients. Targeted at thoracic surgery departments and pulmonologists in Chinese hospitals.
• Service and Support (服务) Comprehensive service offering covering training for medical professionals on Da Vinci robotic surgical system operation, surgical support, and ongoing operational/maintenance services for healthcare institutions using installed systems.

Quantifiable outcome

• 860,000+ patients served with Da Vinci surgical robots
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• 与睿创新 (YuRuiChuangXin)coreTechnology or Integration · 26 May 2024Intuitive Fosun partnered with YuRuiChuangXin to explore AI-powered robotic assisted surgery, focusing on quality improvement and efficiency enhancement in surgical procedures. This collaboration aims to leverage artificial intelligence to advance robotic surgical capabilities.
• Intuitive SurgicalcoreOEM/ Whitelabel/ Licensing PartnerParent company and technology licensor providing the Da Vinci surgical system and Ion navigation technology platform. Intuitive Surgical licenses its proprietary robotic surgical technology to Intuitive Fosun for localization, manufacturing, and distribution in China.
• Fosun (复星)coreStrategic or Co-development PartnerCo-founder and strategic partner providing local market expertise, manufacturing capabilities, regulatory navigation, and distribution network in China. Fosun Healthcare's established presence enables Intuitive Fosun's localization strategy under the '中国制造、共同研发、全球销售' (Made in China, Joint R&D, Global Sales) mandate.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Edge Medical Robotics: China-based surgical robotics developer with laparoscopic robotic systems positioned as lower-priced domestic alternatives to Da Vinci; the most direct China-market peer in robotic-assisted minimally invasive surgery.
• CMR Surgical: UK-based Versius surgical robotics system competing directly with Da Vinci in modular, portable soft-tissue robotic surgery, with growing presence in select Asia-Pacific markets.
• Toumai Robotics (Shanghai Microport MedBot): Chinese developer of the Toumai laparoscopic surgical robot under MicroPort, an emerging domestic competitor directly targeting Da Vinci's hospital accounts in China with lower-priced systems.

Regional players

• Medicaroid: Japan-based developer of the Hinotori surgical robot system, a Da Vinci competitor primarily serving the Japanese market but with strategic interest in broader Asia-Pacific expansion.

Broad incumbents

• Intuitive Surgical: Global leader in robotic-assisted surgery and parent technology licensor to Intuitive Fosun. Operates the same Da Vinci and Ion platforms worldwide, including in direct competition with its own JV in China.
• Medtronic: Developer of the Hugo robotic-assisted surgery platform, a direct global competitor to Da Vinci. As a broad incumbent with deep hospital relationships across Asia, it competes for the same hospital procurement budgets.
• Stryker: Mako robotic-arm assisted surgery platform for orthopedics, representing a major incumbent in surgical robotics with comparable hospital sales motion and capital equipment economics.
• Johnson & Johnson (MedTech): Developer of the Ottava robotic surgery platform (in development) and owner of the MONARCH platform for lung biopsy — overlapping with Intuitive Fosun's Ion system in the lung-nodule indication.

Emerging players

• Noah Medical: Developer of the Ion-derived Galaxy System for lung nodule biopsy and therapy, directly competing with Intuitive's Ion in the same peripheral lung nodule diagnosis use case globally.
• Shurui Robot (Surgerii): China-based developer of single-port and multi-port surgical robotic systems; emerging domestic peer with overlapping use cases in urology, gynecology, and thoracic surgery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/intuitive-surgical-fosun-hongkong

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intuitive Fosun Hong Kong